Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease

Neurobiology of Aging

Volumn 18, Issue 4, 1997, Pages 415-421

  Webster, S ^a   Lue, L F ^b   Brachova, L ^b   Tenner, A J ^a   McGeer, P L ^c   Terai, K ^c   Walker, D G ^c   Bradt, B ^d   Cooper, N R ^d   Rogers, J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SUN HEALTH RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Alzheimer's disease; Brain; Complement; Inflammation

Indexed keywords

AMYLOID BETA PROTEIN; COMPLEMENT COMPONENT C5; COMPLEMENT MEMBRANE ATTACK COMPLEX;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; ELECTRON MICROSCOPY; ENCEPHALITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INFLAMMATION; LIGHT; NEUROFIBRILLARY TANGLE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0030817147     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-4580(97)00042-0     Document Type: Article

References (23)

1. Brachova L., Lue L.-F., Schultz J., ElRashidy T., Rogers J. Association cortex, cerebellum, and serum concentrations of C1q and factor B in Alzheimer's disease. Mol. Brain Res. 18:1993;329-334.
2. Bradt B. M., Bixby T. S., Kolb W. P., Cooper N. R. Covalent binding of Alzheimer's disease Aβ peptide with C3 via activation of both complement pathways. Mol. Immunol. 33:(Suppl.):1996;27.
3. Discipio R. G., Gehring M. R., Podack E. R., Kan C. C., Hugli T. E., Fey G. H. Nucleotide sequence of cDNA and derived amino acid sequence of human complement component C9. Proc. Nat. Acad. Sci. USA. 81:1984;7298-7302.
4. Eikelenboom P., Hack C. E., Rozemuller J. M., Stam F. C. Complement activation in amyloid plaques in Alzheimer's dementia. Virch. Arch. B Cell Pathol. 56:1989;259-262.
5. Itagaki S., Akiyama H., Saito H., McGeer P. L. Ultrastructural localization of complement membrane attack complex (MAC)-like immunoreactivity in brains of patients with Alzheimer's disease. Brain Res. 645:1994;78-84.
6. Jiang H., Burdick D., Glabe C. G., Cotman C. W., Tenner A. J. β-amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q chain. J. Immunol. 152:1994;5050-5059.
7. Kalaria R. N., Kroon S. N. Complement inhibitor C4-binding protein in amyloid deposits containing serum amyloid P in Alzheimer's disease. Biochem. Biophys. Res. Commun. 186:1992;461-466.
8. Kuby J. Immunology. 1994;393-411 W. H. Freeman and Company, New York.
9. Lue L.-F., Rogers J. Full complement activation fails in diffuse plaques of the Alzheimer's disease cerebellum. Dementia. 3:1992;308-313.
10. May P. C., Lampert-Etchells M., Johnson S. A., Poirier J., Masters J. N., Finch C. E. Dynamics of gene expression for a hippocampal glycoprotein elevated in Alzheimer's disease and in response to experimental lesions in rat. Neuron. 5:1990;831-839.
11. McGeer P. L., Akiyama H., Itagaki S., McGeer E. G. Activation of the classical complement pathway in brain tissue of Alzheimer patients. Neurosci. Lett. 107:1989;341-346.
12. McGeer P. L., Itagaki S., Tago H., McGeer E. G. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci. Lett. 79:1987;195-200.
13. McGeer P. L., McGeer E. G. The inflammatory response system of brain implications for therapy of Alzheimer and other neurodegenerative diseases . Brain Res. Rev. 21:1995;195-218.
14. McGeer P. L., Walker D. G., Akiyama H., Kawamata T., Guan A. L., Parker C. J., Okada N., McGeer E. G. Detection of the membrane inhibitor of reactive lysis (CD59) in diseased neurons of Alzheimer brain. Brain Res. 544:1991;315-319.
15. Podack E. R. Molecular composition of the tubular structure of the membrane attack complex of complement. Proc. Nat. Acad. Sci. USA. 259:1984;8641-8647.
16. Rogers J., Cooper N. R., Webster S., Schultz J., McGeer P. L., Styren S. D., Civin W. H., Brachova L., Bradt B., Ward P., Lieberburg I. Complement activation by β-amyloid in Alzheimer's disease. Proc. Nat. Acad. Sci. USA. 89:1992;10016-10020.
17. Rogers J., Webster S., Lue L.-F., Brachova L., Civin W. H., Emmerling M., Shivers B., Walker D., McGeer P. L. Inflammation and Alzheimer's disease pathogenesis. Neurobiol. Aging. 17:1996;681-686.
18. Scolding N. J., Morgan B. P., Houston W. A. J., Linington C., Campbell A. K., Compston D. A. S. Vesicular removal by oligodendrocytes of membrane attack complexes formed by activated complement. Nature. 339:1989;620-622.
19. Vanguri P., Shin M. L. Activation of complement by myelin identification of C1-binding proteins of human myelin from central nervous tissue . J. Neurochem. 46:1986;1535-1541.
20. Veerhuis R., Janssen I., Hack C. E., Eikelenboom P. Early complement components in Alzheimer's disease brains. Acta Neuropathol. 91:1996;53-60.
21. Veerhuis R., van der Valk P., Janssen I., Zhan S. S., Van Nostrand W. E., Eikelenboom P. Complement activation in amyloid plaques in Alzheimer's disease brains does not proceed further than C3. Virch. Arch. 426:1995;603-610.
22. Walker D. G., McGeer P. L. Complement gene expression in human brain comparison between normal and Alzheimer disease cases . Mol. Brain Res. 14:1992;109-116.
23. Webster S., Glabe C., Rogers J. Multivalent binding of complement protein C1q to the amyloid β-peptide (Aβ) promotes the nucleation phase of Aβ aggregation. Biochem. Biophys. Res. Comm. 217:1995;869-875.